CRESCENT BIOPHARMA, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CRESCENT BIOPHARMA, INC. (CBIO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was -$5.00K, a 100.31% decline year-over-year.
- CRESCENT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $5.00K.
- CRESCENT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- CRESCENT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $51.00K.
- CRESCENT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.68M.
- CRESCENT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $872.89K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 0 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 | $0.00 derived: sum of 3 quarters · filed 2026-07-30 | $51.00K derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $5.00K 10-Q · filed 2026-04-29 | $5.00K derived: sum of 2 quarters · filed 2026-04-29 | $56.00K derived: sum of 3 quarters · filed 2026-04-29 | $1.69M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $51.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.68M derived: sum of 3 quarters · filed 2026-07-30 | $1.68M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.68M derived: sum of 2 quarters · filed 2026-07-30 | $1.68M 10-Q · filed 2025-11-06 | $1.68M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.63M 10-Q · filed 2026-07-30 | $1.63M derived: sum of 3 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-04-29 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $0.00 derived: sum of 2 quarters · filed 2025-02-13 | $872.89K 10-K · filed 2025-02-13 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $872.89K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $872.89K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |